Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days and <18 years) with CD19(+) relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) received up...

Descripción completa

Detalles Bibliográficos
Autores principales: Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rössig, Claudia, Kormany, William N., Viswagnachar, Puneeth, Chen-Santel, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945309/
https://www.ncbi.nlm.nih.gov/pubmed/34979020
http://dx.doi.org/10.1182/bloodadvances.2021005579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945309/
https://www.ncbi.nlm.nih.gov/pubmed/34979020
http://dx.doi.org/10.1182/bloodadvances.2021005579

Ejemplares similares